Radiopharma Collaboration Orbit Discovery actively partners with radiopharmaceutical developers and radiotherapy-focused companies to supply peptide ligands and targeting capabilities for radiopharmaceuticals, indicating a ready channel for BD efforts in cancer theranostics and targeted radiotherapies.

Clinical Pipeline Enablement The company’s peptide display engine delivers biologically relevant peptide therapeutic leads that can be leveraged to de-risk early-stage programs, offering potential sell-in value to biotech partners seeking platform-enabled target discovery and rapid hit generation.

Academic-Industry Access With roots in Oxford and a track record of collaborations across academia and industry, Orbit maintains a favorable stance for joint development, licensing, and sponsored research opportunities that can broaden a partner’s access to novel peptide targets.

Radiopharma Targeting Recent and ongoing collaborations focus on peptide receptor radionuclide therapies and cell-targeting peptides, presenting a clear entry point for BD outreach to radiopharma companies seeking new peptide leads for radiopharmaceuticals.

Growth Indicators A mid-size biotech with a growing collaboration footprint, early-stage revenue and recent grant funding signals a scalable partner ecosystem, suggesting opportunities for services, co-development agreements, and platform licensing deals.